NS Pharma Announces FDA Clearance to Initiate Phase II Study for NS-089/NCNP-02, an Exon 44 Skipping Candidate for the Treatment of Duchenne

April 18, 2023

On Friday, April 14, 2023, NS Pharma announced that the U.S. Food & Drug Administration (FDA) has agreed to the planned Phase II study of NS-089/NCNP02 for Duchenne muscular dystrophy.

Please read the full update on their shared press release.

Accessible Vehicle Fund Applications Open